bpc 157 pharmacokinetics oral BPC-157 and the Difference Between an Evidence Gap and a Cover-Up: What the entire human evidence base actually looks like, and the questions to ask next. — WellFounded BPC-157 Clinical Profile | Research

The anti-pharma industry position is understandable, with many scandals that have plagued the industry (such as Vioxx, Oxycontin, and several others) without any accountability of the companies or their senior management

This article walks through what the three components actually do at the bench, how to reconstitute a copper-containing blend without destroying the GHK-Cu chelate, the IU math on a U100 insulin syringe, and where the blend format helps versus where three separate vials remain the better choice

Peptides are awesome and amazing

The real, untold risk One of the reasons BPC-157 has attracted attention is its potential to support new blood vessel growth during tissue repair

However, oxidation of cysteine residues on KEAP1 including Cys151, Cys273, and Cys288 by H 2 O 2 induces a conformational change in KEAP1 and stimulates the activation of Nrf2 150